Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors

• Main Authors: Xu H, Liu Q
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-01-01
• Series: OncoTargets and Therapy
• Subjects: gist; therapeutic drug monitoring; tdm; imatinib; sunitinib; targeted therapy
• Online Access: https://www.dovepress.com/individualized-management-of-blood-concentration-in-patients-with-gast-peer-reviewed-article-OTT

Hao Xu,1 Qi Liu2 1Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China; 2Trauma Center, The First Hospital of China Medical University, Shenyang, People’s Republic of ChinaCorrespondence: Qi LiuTrauma Center, The First Hospital of China Medical University, Shenyang 110001, People’s Republic of ChinaTel/Fax [phone]Email [e-mail]: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes. According to the current version of the guidelines, most GIST patients receive a fixed dose without taking into account their own individual differences, resulting in a wide difference in blood concentration, adverse reactions and prognosis. With more studies on the relationship between blood drug concentrations and prognosis, the concept of individualized therapy has been paid more attention by researchers. Therapeutic drug monitoring (TDM) has also been made available for the research field of GIST targeted therapy. How to reduce the incidence of drug resistance and adverse reactions in patients with GISTs has become the focus of the current research. This article reviews the common monitoring methods and timing of TKIs blood concentration, the reasonable range of blood drug concentration, the toxic or adverse effects caused by high blood drug concentration, some possible factors affecting blood drug concentration and recent research progress, in order to discuss and summarize the treatment strategy of individual blood drug concentration, improve the prognosis of patients and reduce the adverse effects as much as possible.Keywords: GIST, therapeutic drug monitoring, TDM, imatinib, sunitinib, targeted therapy